Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions.

Int J Mol Sci · 2025 · PMC12250528 · PMID 40649773

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The CheckMate 040 trial showed patients with advanced HCC had an objective response to nivolumab (monoclonal antibody targeting PD-1) monotherapy; however, the phase III CheckMate-459 trial, which compared nivolumab to sorafenib, did not reach statistical significance for median OS (16.4 vs. 14.7 months, HR 0.85; 95% CI, 0.72–1.02) [ 82 , 83 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.